[1]Gruskay JA, Webb ML, Grauer JN. Methods of evaluating lumbar and cervical fusion. Spine J. 2014;14(3):531-539. [2]Malham GM, Parker RM, Ellis NJ, et al. Anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2: a prospective study of complications. J Neurosurg Spine. 2014;21(6):851-860. [3]Liao JC, Chen WJ, Chen LH, et al. Surgical outcomes of degenerative spondylolisthesis with L5-S1 disc degeneration: comparison between lumbar floating fusion and lumbosacral fusion at a minimum 5-year follow-up. Spine (Phila Pa 1976). 2011;36(19):1600-1607. [4]Rezwan K, Chen QZ, Blaker JJ, et al. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials. 2006;27(18): 3413-3431. [5]Grauer JN, Beiner JM, Kwon B, et al. The evolution of allograft bone for spinal applications. Orthopedics. 2005; 28(6):573-577; quiz 578-579.[6]Majid K, Tseng MD, Baker KC, et al. Biomimetic calcium phosphate coatings as bone morphogenetic protein delivery systems in spinal fusion. Spine J. 2011;11(6):560-567. [7]Marie PJ, Debiais F, Haÿ E. Regulation of human cranial osteoblast phenotype by FGF-2, FGFR-2 and BMP-2 signaling. Histol Histopathol. 2002;17(3):877-885. [8]Lad SP, Nathan JK, Boakye M. Trends in the use of bone morphogenetic protein as a substitute to autologous iliac crest bone grafting for spinal fusion procedures in the United States. Spine (Phila Pa 1976). 2011;36(4):E274-281.[9]Boerckel JD, Kolambkar YM, Dupont KM, et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials. 2011;32(22):5241-5251.[10]Autefage H, Briand-Mésange F, Cazalbou S, et al. Adsorption and release of BMP-2 on nanocrystalline apatite-coated and uncoated hydroxyapatite/beta-tricalcium phosphate porous ceramics. J Biomed Mater Res B Appl Biomater. 2009; 91(2): 706-715.[11]Chen L, Gu Y, Feng Y, et al. Bioactivity of porous biphasic calcium phosphate enhanced by recombinant human bone morphogenetic protein 2/silk fibroin microsphere. J Mater Sci Mater Med. 2014;25(7):1709-1719.[12]Gu Y, Chen L, Yang HL, et al. Evaluation of an injectable silk fibroin enhanced calcium phosphate cement loaded with human recombinant bone morphogenetic protein-2 in ovine lumbar interbody fusion. J Biomed Mater Res A. 2011;97(2): 177-185.[13]Murugan R, Ramakrishna S. Bioresorbable composite bone paste using polysaccharide based nano hydroxyapatite. Biomaterials. 2004;25(17):3829-3835.[14]Smucker JD, Bobst JA, Petersen EB, et al. B2A peptide on ceramic granules enhance posterolateral spinal fusion in rabbits compared with autograft. Spine (Phila Pa 1976). 2008;33(12):1324-1329. [15]Blattert TR, Delling G, Dalal PS, et al. Successful transpedicular lumbar interbody fusion by means of a composite of osteogenic protein-1 (rhBMP-7) and hydroxyapatite carrier: a comparison with autograft and hydroxyapatite in the sheep spine. Spine (Phila Pa 1976). 2002;27(23):2697-2705.[16]Lysack JT, Yen D, Dumas GA. In vitro flexibility of an experimental pedicle screw and plate instrumentation system on the porcine lumbar spine. Med Eng Phys. 2000;22(7): 461-468.[17]Abbah SA, Lam CX, Ramruttun AK, et al. Fusion performance of low-dose recombinant human bone morphogenetic protein 2 and bone marrow-derived multipotent stromal cells in biodegradable scaffolds: a comparative study in a large animal model of anterior lumbar interbody fusion. Spine (Phila Pa 1976). 2011;36(21):1752-1759. [18]Smucker JD, Bobst JA, Petersen EB, et al. B2A peptide on ceramic granules enhance posterolateral spinal fusion in rabbits compared with autograft. Spine (Phila Pa 1976). 2008; 33(12):1324-1329. [19]Akita S, Fukui M, Nakagawa H, et al. Cranial bone defect healing is accelerated by mesenchymal stem cells induced by coadministration of bone morphogenetic protein-2 and basic fibroblast growth factor. Wound Repair Regen. 2004;12(2): 252-259.[20]Liu X, Ma PX. The nanofibrous architecture of poly(L-lactic acid)-based functional copolymers. Biomaterials. 2010; 31(2):259-269. [21]Lou T, Wang X, Song G. Fabrication of nano-fibrous poly(L-lactic acid) scaffold reinforced by surface modified chitosan micro-fiber. Int J Biol Macromol. 2013;61:353-358. [22]Chen VJ, Ma PX. Nano-fibrous poly(L-lactic acid) scaffolds with interconnected spherical macropores. Biomaterials. 2004;25(11):2065-2073.[23]Liu X, Won Y, Ma PX. Porogen-induced surface modification of nano-fibrous poly(L-lactic acid) scaffolds for tissue engineering. Biomaterials. 2006;27(21):3980-3987. [24]Qiao C, Zhang K, Jin H, et al. Using poly(lactic-co-glycolic acid) microspheres to encapsulate plasmid of bone morphogenetic protein 2/polyethylenimine nanoparticles to promote bone formation in vitro and in vivo. Int J Nanomedicine. 2013;8:2985-2995. [25]Qiao C, Zhang K, Sun B, et al. Sustained release poly (lactic-co-glycolic acid) microspheres of bone morphogenetic protein 2 plasmid/calcium phosphate to promote in vitro bone formation and in vivo ectopic osteogenesis. Am J Transl Res. 2015;7(12):2561-2572. [26]Atluri K, Seabold D, Hong L, et al. Nanoplex-Mediated Codelivery of Fibroblast Growth Factor and Bone Morphogenetic Protein Genes Promotes Osteogenesis in Human Adipocyte-Derived Mesenchymal Stem Cells. Mol Pharm. 2015;12(8):3032-3042. [27]Jin H, Zhang K, Qiao C, et al. Efficiently engineered cell sheet using a complex of polyethylenimine-alginate nanocomposites plus bone morphogenetic protein 2 gene to promote new bone formation. Int J Nanomedicine. 2014;9: 2179-2190. [28]Xu X, Qiu S, Zhang Y, et al. PELA microspheres with encapsulated arginine-chitosan/pBMP-2 nanoparticles induce pBMP-2 controlled-release, transfected osteoblastic progenitor cells, and promoted osteogenic differentiation. Artif Cells Nanomed Biotechnol. 2017;45(2):330-339. [29]陈亮,顾勇,陈晓庆,等.丝素蛋白增强型磷酸钙复合rhBMP-2用于绵羊腰椎椎体间融合的实验研究[J].中华骨科杂志,2010, 30(7): 677-683.[30]Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med. 2008;2(2-3):81-96. |